A cutely elevated blood pressure (BP) is associated with early mortality and poor clinical outcome in intracerebral hemorrhage (ICH), 1, 2 and this effect may be mediated by hematoma expansion. 3, 4 Early BP treatment may, therefore, be beneficial after ICH, and this hypothesis is being tested in ongoing trials. 5, 6 In contrast, an association between very low admission BPs (systolic BP [SBP] <120 mm Hg) and poor outcome has also been reported. 7 It has been postulated that elevated BP is a homeostatic response to elevated intracranial pressure serving to maintain cerebral blood flow (CBF) 8 and that there is a zone of ischemia surrounding the hematoma referred to as the perihematoma penumbra. 9, 10 Reduced CBF in the perihematoma region has been demonstrated, [11] [12] [13] [14] but the effect of rapid BP reduction on perihematoma and hemispheric flow remains unknown. The potential for precipitation of ischemic injury is the primary rationale underlying guideline statements recommending caution with respect to early BP treatment. 15, 16 We aimed to address the competing treatment rationales by measuring CBF in acute ICH patients randomized to different BP management strategies. Our a priori hypothesis was that early acute BP reduction would not result in significantly lower perihematoma CBF than that in patients managed conservatively.
Methods

Patients
The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial was a multicenter, prospective, randomized, open-label, with blinded evaluation study (ClinicalTrials.gov registration number NCT00963976). The protocol has been published previously. 17 Eligible patients were ≥18 years of age, with spontaneous ICH diagnosed on noncontrast computed tomography (CT) <24 hours after onset. SBP was ≥150 mm Hg (≥2 readings ≥5 minutes apart). Patients with evidence of secondary ICH (eg, vascular malformation), planned surgical resection, or contraindications to CT perfusion (CTP; eg, contrast allergy or renal impairment) were excluded. Informed consent was provided by the patient or surrogate decision maker. The protocol was approved by local human research ethics committees.
Procedures
Randomization and BP Management Protocols
Patients were randomized to an SBP target of <150 mm Hg or <180 mm Hg to be achieved within 1 hour of randomization. A block randomization design (6 patients/block), stratified by onset to treatment time (≤6 and 6-24 hours), was used. Acute BP was treated according to a protocol (Table I in online-only Data Supplement). 17 Noninvasive BP and heart rate monitoring were continued for 24 hours.
Imaging Procedures
Two hours after randomization, all patients underwent standard noncontrast CT (5 mm slices [120 kvp, 300 mA/slice]) through the entire brain (l8-20 slices; 512×512 matrix). A 38-to 80-mm thick CTP section was centered on the slice, where the hematoma had the greatest diameter. The CTP slab thickness and acquisition protocol varied with scanner capabilities, which ranged from 64 to 320 slices at the trial sites, reflecting a pragmatic approach to perfusion acquisition. CTP images were acquired with intravenous iodinated contrast (40-50 mL via 18 g antecubital vein angiocatheter at 4-7 mL/s), with CT images acquired every second for 50 seconds (80 kvp; 200 mA/ image). A repeat noncontrast CT scan was obtained 24±3 hours after randomization.
Clinical Assessments
A National Institutes of Health Stroke Scale (NIHSS) score was assessed by trained personnel blinded to treatment group allocation immediately after the CTP scan, 2±1 hours, 24±3 hours, 30±5 days, and 90±5 days after randomization. Functional outcome was assessed with Barthel Index and modified Rankin Scale at 24 hours, day 30, and day 90 by assessors blinded to BP treatment.
Image Analysis
Images were postprocessed and measured centrally by readers (B.G. and R.M.) blinded to clinical outcome and treatment group. Hematoma, intraventricular hemorrhage, and total ICH (hematoma+intraventricular hemorrhage) volumes were calculated using planimetric techniques. Raw CTP source images were transferred to a computer workstation and analyzed using the PerfScape analysis package (Olea Medical, Marseilles). CTP maps were derived from tissue time-density curves, based on the change in x-ray film attenuation, which is linearly related to contrast concentration, over time. Errors introduced by delay and dispersion of the contrast bolus before arrival in the cerebral circulation were corrected with singular value deconvolution and quantitative CBF, and cerebral blood volume (CBV) maps were generated on a voxelwise basis. 18 Perfusion maps were transferred to the Analyze 11.0 software package (Biomedical Imaging Resource, Mayo Clinic) for region of interest analysis. The perimeter of the hematoma was determined on the precontrast CT source image using an intensity threshold technique. A region of interest was drawn 1 cm from the perimeter of the hematoma, excluding intraventricular and subarachnoid spaces. 11 Voxels containing blood vessels were removed from the regions of interest using an intensity threshold (CBF >100 mL/100 g per minute or CBV >8 mL/100 g). 18 The magnitude of flow changes in the perihematoma region was calculated as the mean CBF or CBV of all voxels. To assess global changes, mean perfusion indices were also measured in the entire hemisphere ipsilateral and contralateral to the hematoma. After calculation of absolute values, all perfusion parameters were standardized as changes relative (r) to unaffected contralateral homologous regions.
Statistical Analysis
Power calculations indicated that 31 evaluable patients were required to detect a 15% difference in perihematoma relative CBF (rCBF) between treatment groups (90% power; 2-tailed α=0.05). 17 We planned to test the primary end point of perihematoma rCBF using ANCOVA, adjusting for baseline hematoma volume 11 and time to randomization. Initial data exploration revealed the assumptions of ANCOVA were violated because the slopes of the relationship between volume and CBF across time strata were different. Therefore, we tested the primary hypothesis with a generalized linear model adjusting for baseline ICH volume and time to randomization. BP differences between treatment groups at each time point were considered different when the 95% confidence intervals (CIs) of the means did not overlap. The frequency of risk factors at baseline, mortality, and clinical deterioration were compared using Pearson and Fisher exact χ 2 tests. Absolute differences in perfusion parameters between ipsilateral and contralateral regions within patients were assessed with paired t tests. Intergroup comparisons of normally and non-normally distributed variables were assessed with unpaired t tests and Wilcoxon tests, respectively. The relationship between absolute BP change and perihematoma rCBF was explored using linear regression.
Results
A total of 456 patients were screened between January 28, 2007, and December 6, 2011, and 75 patients were randomized. The most common reasons for not enrolling patients were evidence of secondary ICH, including trauma, inability to randomize within 24 hours, and a presenting SBP <150 mm Hg ( Figure 1 ).
Baseline Characteristics
The treatment groups were balanced with respect to baseline demographics, including a history of hypertension, treatment with antihypertensives, BP, time to enrollment, and hematoma location (Table 1) .
BP Management
All patients in the <150 mm Hg target group were treated with intravenous antihypertensive agents, and the mean dose of all drugs was significantly higher than that used in the <180 mm Hg target group (Table II in the online-only Data Supplement). Patients in the latter group were treated with intravenous antihypertensive drugs in 44% of cases. Mean SBP was significantly lower in the <150 mm Hg target group within 30 minutes of randomization ( Figure 2 ). Mean SBP and diastolic BP in the <150 mm Hg target group were both significantly lower than that in the <180 mm Hg target group immediately before CTP acquisition (Table II in the onlineonly Data Supplement). The mean SBP at the time of the CTP scan was 140±19 mm Hg and 162±12 mm Hg in the <150 and <180 mm Hg target groups, respectively. The target BP was achieved in 79% and 100% of patients at the time of the CTP scan in the <150 and <180 mm Hg target groups, respectively (P=0.005).
Cerebral Perfusion and BP
Focal decreases in CBF and CBV within the perihematoma region were evident in all patients (Figure 3 ). Mean absolute CBF was 38.7±11.9 mL/100 g per minute in the perihematoma region and 44.1±11.1 mL/100 g per minute in the contralateral homologous region (absolute difference, 5.4±4.6 mL/100 
Primary Outcome
After adjustment for baseline intraparenchymal hematoma volume and time to randomization, perihematoma rCBF was not significantly lower in patients randomized to a target SBP of <150 mm Hg (0.86±0.12) than in those in the <180 mm Hg target group (0.89±0.09; P=0.18; absolute difference,0.03; 95% CI, −0.018 to 0.078). The actual sample size allows us to reject the hypothesis that rCBF differs between treatment groups by >15% (absolute difference of 0.135) with 99% power. The results of an unadjusted analysis were nearly identical ( Table 2 ). Linear regression indicated no relationship between perihematoma rCBF and the absolute change in SBP in the <150 mm Hg target group (R=0.00005; 95% CI, −0.001 to 0.001) or <180 mm Hg target group (R=0.000; 95% CI, −0.001 to 0.001; Figure 4 ). Perihematoma rCBV was also similar between the 2 treatment groups (0.90±0.14 vs 0.91±0.15; P=0.73).
The interval between symptom onset and BP treatment did not affect cerebral perfusion or the response to BP treatment. There were no overall differences in perihematoma rCBF between patients randomized within 6 hours (0.86±0.11) relative to those treated 6 to 24 hours after onset (0.89±0.10; P=0. 20) . BP treatment did not affect rCBF in patients treated within 6 hours (0.78±0.22 in the <150 mm Hg group and 0.88±0.10 in the <180 mm Hg group; P=0.08; absolute difference, 0.10; 95% CI, −0.020 to 0.22) or in those treated 6 to 24 hours after onset (0.85±0.21 in the <150 mm Hg group and 0.89±0.10 in the <180 mm Hg group; P=0.46; absolute difference, 0.04; 95% CI, −0.07 to 0.15). There was no significant interaction between time to randomization and treatment group with respect to rCBF (P=0.25 for interaction). Similarly, among patients with large ICH volumes (>30 mL), perihematoma rCBF was not affected by treatment: 0.88±0.10 mL/100 g per minute in the <150 mm Hg target group (n=10) and 0.87±0.09 mL/100 g per minute in the <180 mm Hg target group (n=12; P=0.82). There was no significant interaction between volume and treatment group (P=0.73 for interaction).
Hemispheric CBF, Hematoma Expansion, and Clinical Outcome
Ipsilateral hemispheric rCBF (a prespecified secondary end point) was lower in patients randomized to the <150 mm Hg target group (0.95±0.05), relative to those in the <180 mm Hg target group (0.99±0.05; P=0.0013). Absolute hemispheric CBF in the <150 mm Hg group was only 2.07±2.40 mL/100 g per minute lower than that in the contralateral hemisphere (P<0.0001). Absolute ipsilateral hemispheric CBF in the <150 mm Hg group (42.42±12.05 mL/100 g per minute) was not different than that in the <180 mm Hg group (41.79±8.68; P=0.80). Finally, the observed reduction in ipsilateral hemispheric rCBF was not associated with a decrease in hemispheric rCBV (Table 2) .
Total ICH volume growth between the baseline noncontrast CT and the CTP scan was similar between the 2 treatment groups (Table 2 ). Mortality and neurological and functional disability scale scores between 2 hours and 90 days postrandomization were all comparable between treatment groups. Neurological deterioration, defined as an increase in the NIHSS score of ≥4 points, occurred in 
Discussion
In this trial, early BP treatment had no effect on perihematoma CBF and was associated with a modest reduction in ipsilateral hemispheric rCBF. These results do not support the hypothesis that a treatment-related ischemic penumbra within the perihematoma region exists.
Relative perihematoma hypoperfusion in acute/subacute ICH patients has been described previously. [11] [12] [13] [14] A single study evaluated the effects of BP reduction on CBF. 19 Fourteen ICH patients were treated 6 to 22 hours after onset, and CBF was measured with positron emission tomography. Consistent with our own findings, a reduction target of 15% from baseline was not associated with significant perihematoma or global CBF decreases. In addition, our results suggest that a more aggressive absolute target of <150 mm Hg did not reduce CBF, relative to conservatively managed patients, even when treatment was initiated earlier and in those with larger hematoma volumes. We also found no consistent relationship between the magnitude of the BP drop and perihematoma CBF.
There are 2 other prospective studies of the clinical safety of acute BP reduction in ICH patients. A nonrandomized trial of 60 ICH patients treated with nicardipine (SBP lowered to target tiers between 110 and 200 mm Hg) demonstrated no adverse events. 20 The only randomized investigation of BP reduction in ICH is the INTensive Reduction of Acute BP in Cerebral Hemorrhage Trial (INTERACT). 21 Acute ICH patients were randomized to <140 mm Hg versus <180 mm Hg SBP target groups within 6 hours of onset. Clinical deterioration was not more common after intensive antihypertensive therapy, which was also associated with a trend to lower rates of ICH expansion (15% in the <140 mm Hg vs 23% in <180 mm Hg group). Our data support the safety of this absolute SBP target approach, rather than a fractional treatment reduction based on the presenting pressure. As in our trial, BP in conservatively managed INTERACT patients gradually declined in the first hours after onset. 21 Despite this natural history, it is clear that rapid reduction is not easily achieved (77% <150 mm Hg in our study and 42% <140 mm Hg in INTERACT) 21 and requires intensive monitoring/treatment.
The perihematoma region has been studied with diffusionweighted MRI (DWI). The DWI characteristics within the perihematoma region are consistent with vasogenic edema, 11 and possibly inflammatory/mechanical cellular injury, 12 rather 
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than ischemic changes. A more recent MRI study demonstrated small areas of discrete diffusion restriction, consistent with ischemic injury, distinct from the perihematoma region in one third of acute ICH patients. 22 Although there was an association with BP reduction, this observation was retrospective. Whereas it is possible that the modest reduction in ipsilateral hemispheric rCBF in the <150 mm Hg target group in our trial is linked mechanistically to DWI lesion development, this appears unlikely for several reasons. The absolute reduction in CBF is minute, does not reach ischemic thresholds, 18 and is not associated with a fall in CBV (an indicator of ischemic tissue injury). In addition, DWI lesions were reported with equal frequency in both the ipsilateral and contralateral hemispheres, 22 and we observed no differences in CBF associated with BP reduction in the latter. Nonetheless, a randomized study of acute BP reduction followed by DWI assessment will be required to definitively address any link between BP and these lesions.
We did not observe differences in ICH expansion rates or clinical outcomes in this trial, which was underpowered to assess these events. These were secondary end points included for hypothesis generation only because larger studies, such as the ongoing INTERACT II 5 and Antihypertensive Treatment of Acute Cerebral Hemorrhage II 66 trials, will be required to demonstrate differences in these outcomes. Our results support the safety of these trials.
Patients with contraindications to CTP were excluded from this study, particularly those with renal failure. Thus, many patients with advanced small vessel changes secondary to hypertension/diabetes mellitus were not assessed. In addition, patients who were too medically unstable to undergo CTP were excluded, which likely limited the number of very large hematomas in our study. We had planned to analyze patients with ICH volumes >50 mL separately, but revised this to >30 mL based on actual volumes in our study. Thus, it remains possible that patients with very large ICH volumes will exhibit worsening of CBF in response to BP reduction. Difficulty assessing outcomes in large ICH, beyond early mortality, is not unique to this study, given the poor prognosis. 15 A technical limitation is the multiple CT scanners used to acquire perfusion images, necessitated by the multicenter design. Central analysis of all raw CTP data by blinded raters ensured postprocessing techniques were uniform, but the possibility of differences in acquisition protocols affecting our data cannot be excluded. These effects will have been minimized with respect to the primary outcome because it was a relative measure of CBF, resulting in data standardization. A further limitation of our study is the relatively small number of patients randomized <3 hours from onset, the time at which BP reduction is most likely to attenuate ICH expansion. 21 Nonetheless, we found no relationship between time to randomization and CBF, both when time was included in our generalized linear model and when results were analyzed separately by randomization strata (0-6 vs 6-24 hours). Inclusion of only hyperacute patients may also have minimized the confounding effects of spontaneous BP decreases with time. This would have limited recruitment to a very small number of patients. In addition, the effects of BP reduction on CBF remain relevant at later time points.
We find no evidence that cerebral ischemia is precipitated by rapid BP reduction with intravenous antihypertensive agents in acute ICH patients, with moderate hematoma volumes. These results support the safety of randomized trials of BP reduction after ICH. 
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